Navigation Links
Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

PT. RICHMOND, Calif., Jan. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference at the Grand Hyatt Hotel in New York City on Tuesday, February 5, 2008 at 8:40 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to file an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
2. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... In the United ... 300,000 people each year develop other types of metastatic brain tumors(3). Though most meningiomas ... brain(3). As efforts focus on finding more effective treatment options, the San Diego ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... or without a referral to new patients from Burnaby, BC. Patients in need ... full mouth reconstruction services, can see the esteemed team at Wall Centre Dental. ...
(Date:3/29/2017)... MINNETONKA, Minn. (PRWEB) , ... March 29, 2017 ... ... of medical office buildings (MOBs) and other outpatient facilities, and who are the ... look exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... ... process in many scientific laboratories. The assembly protocols involve many repetitive steps and ... suited for automation, which enables the high-throughput needed, and results in a lower ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology: